ArticleAbdominal radiology (New York)2026
Limited incremental prognostic value of pretreatment MRI and
Article in Abdominal radiology (New York), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMultiparametric MRI (mpMRI) and prostate-specific membrane antigen (PSMA) PET are increasingly used for pretreatment staging of prostate cancer, but their incremental prognostic value for progression-free survival (PFS) beyond clinical variables remains uncertain.
objectiveTo evaluate whether mpMRI and PSMA PET features independently predict PFS in grade group 3 or higher prostate cancer and add value beyond clinical variables.
methodsThis single-center retrospective study included patients with biopsy-proven grade group 3 or higher prostate adenocarcinoma who underwent mpMRI followed by
resultsIn the primary cohort, 22 of 101 patients (22%) progressed (median follow-up, 3.2 years). Univariably, lower minimum and mean tumor ADC were associated with progression (P = 0.026 and 0.029). In the predefined reduced multivariable model, PI-RADS 5 retained an independent association with worse PFS (HR 5.69, 95% CI 1.13 to 28.65; P = .035; Firth HR 4.44, P = .026), whereas normalized ADC and intensity-based PSMA PET metrics did not. Adding imaging to clinical variables improved neither model fit (likelihood ratio P = .457) nor discrimination (optimism-corrected C-index, 0.77 clinical-only versus 0.73 clinical-plus-imaging). PRIMARY 5 versus 1-4 was not associated with PFS (HR 1.09, 0.45 to 2.60; P = 0.852).
conclusionRoutine quantitative MRI and PSMA PET intensity metrics did not independently predict PFS or improve discrimination beyond clinical variables in grade group 3 or higher prostate cancer. Given the event count, this is a failure to detect incremental value rather than evidence of its absence. The PI-RADS 5 association was imprecisely estimated and is hypothesis-generating.
Indexed as
Identifiers
42747479What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.